Success Metrics

Clinical Success Rate
97.2%

Based on 35 completed trials

Completion Rate
97%(35/36)
Active Trials
0(0%)
Results Posted
29%(10 trials)
Terminated
1(3%)

Phase Distribution

Ph not_applicable
1
3%
Ph phase_3
18
46%
Ph phase_4
14
36%
Ph phase_2
3
8%
Ph phase_1
1
3%

Phase Distribution

1

Early Stage

3

Mid Stage

32

Late Stage

Phase Distribution37 total trials
Phase 1Safety & dosage
1(2.7%)
Phase 2Efficacy & side effects
3(8.1%)
Phase 3Large-scale testing
18(48.6%)
Phase 4Post-market surveillance
14(37.8%)
N/ANon-phased studies
1(2.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

97.2%

35 of 36 finished

Non-Completion Rate

2.8%

1 ended early

Currently Active

0

trials recruiting

Total Trials

39

all time

Status Distribution
Completed(35)
Terminated(1)
Other(3)

Detailed Status

Completed35
unknown3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
39
Active
0
Success Rate
97.2%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (2.7%)
Phase 23 (8.1%)
Phase 318 (48.6%)
Phase 414 (37.8%)
N/A1 (2.7%)

Trials by Status

terminated13%
completed3590%
unknown38%

Recent Activity

Clinical Trials (39)

Showing 20 of 39 trialsScroll for more
NCT05184179

Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab

Completed
NCT00382213Phase 3

A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis

Completed
NCT05033535Phase 2

s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension

Unknown
NCT00523744Phase 3

Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension

Completed
NCT00649389Phase 3

Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension

Completed
NCT01132768Phase 4

The Confirmatory Olmesartan Plaque Regression Study

Terminated
NCT00220220Phase 3

Amlodipine as add-on to Olmesartan in Hypertension

Completed
NCT00185133Phase 3

Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension

Completed
NCT00676845Phase 3

Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection

Completed
NCT00220233Phase 3

Olmesartan as an add-on to Amlodipine in Hypertension

Completed
NCT02848170Not Applicable

Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

Completed
NCT01684748Phase 4

Angiotensin II Blockade and Inflammation in Obesity

Completed
NCT02495324Phase 4

Fimasartan Achieving SBP Target (FAST) Study

Completed
NCT01611077Phase 4

Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg

Completed
NCT00403481Phase 4

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

Completed
NCT00151775Phase 2

Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure

Completed
NCT02407210Phase 3

Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension

Unknown
NCT00417222Phase 3

Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan

Completed
NCT01907373Phase 4

Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers

Completed
NCT00185120Phase 4

Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker

Completed

Drug Details

Intervention Type
DRUG
Total Trials
39